Genomic Vision & European Equity Partners Enter into Agreement to Use Molecular Combing as a Genome Integrity Assay in the Fi...
August 09 2018 - 1:45AM
Business Wire
- Genomic Vision grants European Equity
Partner (EEP) a license to its proprietary technology.
- During the evaluation period, the
parties will confirm interest of molecular combing as a genome
integrity assay as a quality control tool in biomanufacturing of
proteins
- This strategic collaboration is aimed
at building a Bioanalytical Services Company offering specific
leading analytical services in bioprocessing.
Regulatory News:
Genomic Vision (Paris:GV) (FR0011799907 – GV), a company
specializing in the development of diagnostic tests for the early
detection of cancers and hereditary diseases, and applications for
life sciences research, today announces that it has entered into a
licensing agreement with European Equity Partners (EEP), a U.K
private investment firm focused on life science investments, to use
molecular combing technology within the bioprocessing domain.
Pursuant to this agreement, the parties will enter into a period
during which they will confirm that the Combing Genome Integrity
assay can replace or complete existing quality control test in
Bioprocessing.
Followed a conclusive development program the two parties plan
to establish of a new entity dedicated to applications of the
Combing Genome Integrity assay in Biomanufacturing. This entity
will have an exclusive license to Genomic Vision’s proprietary
Molecular Combing technology in the field of Biomanufacturing.
The new company will offer a mixed model of analytical services
as well as license agreements to strategic partners using Genome
Integrity Assay for the production of biological products such as
therapeutic proteins, monoclonal or polyclonal antibodies, vaccines
and viral particles.
In exchange of the license right, Genomic Vision will receive an
upfront, milestones payments (amounting to a total of more than 500
k€) as well as royalties on sales and services (other financial
terms not disclosed).
David Kauffmann, founder partner of European Equity Partners,
said: “We believe in the potential of the Genomic Vision
proprietary technology for controlling the quality of Bioproduction
where there is an important unmet need for new assays allowing the
identification and quantification of genomic instability in cell
populations. We are very excited by the idea of setting up
analytical solutions based on this technology that will be
perfectly adapted as quality control tool for cell banks clonality.
These solutions will pave the way to better selection of
appropriate clones and should lead to the improvement of cost
effectiveness in process development and manufacturing”.
Stephane Altaba, Vice President Corporate Development of
Genomic Vision, added: « We are very pleased of this
partnership with EEP who has a great knowhow and knowledge in
building business in the bioprocessing domain, in particular in the
manufacturing of biological products. This agreement confirms the
potential of the combing technology in monitoring genome
instability for therapeutic recombinant proteins and monoclonal
antibodies production - as we already demonstrated its benefits in
gene editing with our partnership with Editas Medecine. In
addition, with a new service activity in the field of
Biomanufacturing, Genomic Vision has the opportunity to access a
high added value and recurrent service revenue stream. We are
looking forward to progress with EEP to create a new way to find
innovative solutions to improve and secure quality of bioproduction
for the benefit of pharma manufacturers and patients”.
ABOUT EUROPEAN EQUITY PARTNERS (EEP)
Based in London (United Kingdom), European Equity Partner (EEP)
is a private investment firm focused on life science investments.
It selectively looks to invest in small and mid-sized life science
companies. The prospect of growth, proven business traction and a
demonstrated promising business model are key investment parameters
for EEP. As an active shareholder, EEP favours companies where its
experience can assist management accelerate growth and optimize
results. For further information, please visit: www.eeplp.com
ABOUT GENOMIC VISION
GENOMIC VISION is a company specialized in the development of
diagnostic solutions for the early detection of cancers and serious
genetic diseases and tools for life sciences research. Through the
DNA Molecular Combing, a strong proprietary technology allowing to
identify genetic abnormalities, GENOMIC VISION stimulates the
R&D productivity of the pharmaceutical companies, the leaders
of the diagnostic industry and the research labs.
The Company develops a robust portfolio of diagnostic tests
(breast, ovarian and colorectal cancers, myopathies) and analysis
tools (DNA replication, biomarkers discovery, gene editing quality
control). Based near Paris, in Bagneux, the Company has
approximately 50 employees. GENOMIC VISION is a public listed
company listed in compartment C of Euronext’s regulated market in
Paris (Euronext: GV - ISIN: FR0011799907). For further information,
please visit: www.genomicvision.com
FORWARD LOOKING STATEMENT
This press release contains implicitly or explicitly certain
forward-looking statements concerning Genomic Vision and its
business. Such forward-looking statements are based on assumptions
that Genomic Vision considers to be reasonable. However, there can
be no assurance that such forward-looking statements will be
verified, which statements are subject to numerous risks, including
the risks set forth in the “Risk Factors” section of the reference
document dated March 28, 2017, available on the web site of Genomic
Vision (www.genomicvision.com) and to the development of economic
conditions, financial markets and the markets in which Genomic
Vision operates. The forward-looking statements contained in this
press release are also subject to risks not yet known to Genomic
Vision or not currently considered material by Genomic Vision. The
occurrence of all or part of such risks could cause actual results,
financial conditions, performance or achievements of Genomic Vision
to be materially different from such forward-looking
statements.
This press release and the information contained herein do not
constitute and should not be construed as an offer or an invitation
to sell or subscribe, or the solicitation of any order or
invitation to purchase or subscribe for Genomic Vision shares in
any country. The distribution of this press release in certain
countries may be a breach of applicable laws. The persons in
possession of this press release must inquire about any local
restrictions and comply with these restrictions.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180808005679/en/
Genomic VisionAaron Bensimon, +33 1 49 08 07
50Co-founder, Chairman &
CEOinvestisseurs@genomicvision.comorUlysse
CommunicationPress RelationsBruno Arabian, +33 1 42 68
29 70barabian@ulysse-communication.comorNewCapInvestor
RelationsDušan Orešanský / Emmanuel Huynh, +33 1 44 71 94
92gv@newcap.eu
Genomic Vision (EU:GV)
Historical Stock Chart
From Mar 2024 to Apr 2024
Genomic Vision (EU:GV)
Historical Stock Chart
From Apr 2023 to Apr 2024